US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

Sterile Curcumin 50mg/mL

Reason Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin

BIOTA Biosciences LLC D-1330-2020
Class II · Moderate risk Terminated

Sterile Cannabidiol

Reason Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin

BIOTA Biosciences LLC D-1329-2020
Class II · Moderate risk Terminated

Sterile Cannabidiol

Reason Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin

BIOTA Biosciences LLC D-1328-2020
Class II · Moderate risk Terminated

Sterile Curcumin

Reason Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin

BIOTA Biosciences LLC D-1327-2020
Class II · Moderate risk Terminated

Sterile Cannabidiol

Reason Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin

BIOTA Biosciences LLC D-1326-2020
Class II · Moderate risk Terminated

Carbamazepine Tablets

Reason Failed Dissolution Specifications

Torrent Pharma Inc. NDC 13668-268-05 D-1317-2020
Class II · Moderate risk Terminated

Aloprim

Reason Discoloration: Out-of-specification results for appearance obtained during routine stability testing at the end of shelf-life for the parameters Appearance and Color of Solution.

Mylan Institutional LLC D-1271-2020
Class II · Moderate risk Terminated

Infuvite PEDiatric Pharmacy

Reason Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins

Sandoz, Inc NDC 54643-5647-0 D-1259-2020
Class II · Moderate risk Terminated

Ketorolac Tromethamine Injection

Reason Presence of Particulate Matter - found in reserve sample vials at the firm.

Fresenius Kabi USA, LLC NDC 63323-162-03 D-1297-2020
Class II · Moderate risk Terminated

Lisinopril Tablets USP

Reason Product Mix-Up: a complaint received indicating mix-up of 10 mg Lisinopril tablets inside of 2 sealed bottles of 20 mg/1000 count bottles.

Lupin Pharmaceuticals Inc. NDC 68180-0981-03 D-1250-2020
Class II · Moderate risk Terminated

Nizatidine Oral Solution

Reason CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

Amneal Pharmaceuticals of New York, LLC NDC 60846-301-15 D-1253-2020
Class II · Moderate risk Terminated

Cefixime for Oral Suspension USP

Reason Subpotent Drug: low out of specification (OOS) test result observed in long term stability study.

Lupin Pharmaceuticals Inc. NDC 68180-405-01 D-1252-2020
Class II · Moderate risk Terminated

Estradiol

Reason cGMP deviations: Presence of foreign material (Teflon)introduced at the production level.

B & B Pharmaceuticals, Inc. NDC 63275-9900-8 D-1244-2020
Class II · Moderate risk Terminated

Levothyroxin

Reason Lack of Processing Control

The Medicine Shoppe Pharmacy D-1228-2020
Class II · Moderate risk Terminated

Bi-Est

Reason Lack of Processing Control

The Medicine Shoppe Pharmacy D-1218-2020